Search
Displaying 101–110 of 147 for “Visions 2020”
-
Foundation News
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Foundation Fighting Blindness Launches Chapter Program Rebrand
Foundation NewsThe program honors Lulie Gund and her legacy and commitment to the Foundation’s Chapter community.
-
Erin’s Unwavering Determination, Then and Now
Beacon StoriesDiagnosed with retinitis pigmentosa at a very young age, growing up, Erin never let her progressive vision loss stop her from keeping up with her friends and siblings. Throughout the 1990s, Erin was featured in several Foundation Fighting Blindness campaigns to raise funds for retinal research. Today, 34-year-old Erin is resilient as ever, still hopeful research will one day find her a cure.
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
In the PressDevelopment of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Beacon Stories
Jenny was diagnosed with retinitis pigmentosa (RP), just like her mom, at the age of 34. In her own words, Jenny shares her experience with being diagnosed with RP and her journey to accepting it with hopefulness.
-
Beacon Stories
At seven years old, Hannah had never seen a lightning bug in the summer or a star in the sky. But after her treatment with LUXTURNA, Hannah can now play outside at night with her brothers and has a new bright future in store.
-
In the Press
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
Foundation News
Mr. Ginsberg brings twenty-five years of rare disease corporate development, finance, strategy, and investment leadership experience.
.jpg)
